Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Gardasil in Chinese Subjects
NCT00496626Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Primary completion
- Feb 2009
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing Gardasil with Placebo (2 arms). Primary endpoint: Geometric Mean Titer of Anti-HPV 6, 11, 16, 18 at Month 7. Started Jul 2008; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00496626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496626.